{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:34:08Z","timestamp":1787762048631,"version":"build-2784847793"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"\n Meta-analysis studying the role of verapamil in improving C-peptide in people with recent-onset type-1 diabetes (T1DM) has not been conducted to date. We undertook this meta-analysis to address this knowledge gap. Electronic databases were systematically reviewed for RCTs having individuals with T1DM receiving verapamil in the treatment arm and placebo in the control arm over the standard of care. The primary outcome was to evaluate changes in the C-peptide area under the curve (AUC) at a one-year follow-up. Secondary outcomes were to assess alterations in C-peptide AUC, glycated hemoglobin (HbA1c), blood pressure, heart rate, and side effects at different time intervals over a one-year follow-up. From the initially screened 27 articles, data from two RCTs (112 patients) satisfied the inclusion criteria and were analyzed. Compared to placebo, C-peptide AUC in individuals receiving verapamil was not different at three months [MD 0.17 nmol\/L (95%CI: -0.05-0.38);\n P<\/jats:italic>\n = 0.13; I\n 2<\/jats:sup>\n = 86%] but significantly higher at 1-year [MD 0.27 nmol\/L (95%CI: 0.19\u20130.35);\n P<\/jats:italic>\n < 0.01; I\n 2<\/jats:sup>\n = 12%]. The verapamil arm showed similar changes in HbA1C at three months [MD 0.23% (95%CI: -0.43\u20130.90);\n P<\/jats:italic>\n = 0.49; I\n 2<\/jats:sup>\n = 88%] and 1-year [MD 0.18% (95% CI: -0.74 \u2013 1.10);\n P<\/jats:italic>\n = 0.70; I\n 2<\/jats:sup>\n = 89%] compared to placebo. Occurrence of treatment-emergent adverse events [Risk ratio (RR) 1.90 (95%CI: 0.52\u20136.91);\n P<\/jats:italic>\n = 0.33; I\n 2<\/jats:sup>\n = 63%], serious adverse events [RR 1.40 (95%CI: 0.50\u20133.93);\n P<\/jats:italic>\n = 0.53], constipation [RR4.11 (95%CI: 0.93\u201318.13);\n P<\/jats:italic>\n = 0.06; I\n 2<\/jats:sup>\n = 0%], headache [RR0.48 (95%CI: 0.16\u20131.43);\n P<\/jats:italic>\n = 0.19; I\n 2<\/jats:sup>\n = 0%], severe hypoglycemia [RR 0.87 (95%CI: 0.06 \u2013 13.51);\n P<\/jats:italic>\n = 0.92] were comparable across groups. Verapamil was well tolerated, and its use over one year was associated with significant improvements in C-peptide AUC though the HbA1c remained unchanged.\n <\/jats:p>","DOI":"10.4103\/ijem.ijem_122_23","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T02:02:39Z","timestamp":1687744959000},"page":"192-200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis"],"prefix":"10.4103","volume":"27","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Center for Endocrinology Diabetes Arthritis and Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, JSS Academy of Higher Education and Research, Mysore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Raizada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Center for Endocrinology Diabetes Arthritis and Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/(SICI)1096-9136(199810)15:10<844::AID-DIA679>3.0.CO;2-A","article-title":"Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus","volume":"15","author":"Bonfanti","year":"1998","journal-title":"Diabet Med"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2337\/db07-0715","article-title":"Thioredoxin-interacting protein:A critical link between glucose toxicity and beta-cell apoptosis","volume":"57","author":"Chen","year":"2008","journal-title":"Diabetes"},{"key":"R4-20240828","first-page":"243","article-title":"TXNIP inhibition in the treatment of diabetes:Verapamil as a novel therapeutic modality in diabetic patients","volume":"95","author":"Borowiec","year":"2022","journal-title":"Med Pharm Rep"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","article-title":"Verapamil and beta cell function in adults with recent-onset type 1 diabetes","volume":"24","author":"Ovalle","year":"2018","journal-title":"Nat Med"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2023.2064","article-title":"Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes:A randomized clinical trial","volume":"329","author":"Forlenza","year":"2023","journal-title":"JAMA"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes:A meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"102697","DOI":"10.1016\/j.dsx.2022.102697","article-title":"Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis","volume":"17","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE:An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2213-8587(22)00351-5","article-title":"FDA approves teplizumab:A milestone in type 1 diabetes","volume":"11","author":"Hirsch","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk:A Randomized, Double-Masked, Controlled Trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jama.2023.2063","article-title":"Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes:A randomized clinical trial","volume":"329","author":"McVean","year":"2023","journal-title":"JAMA"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc22-0908","article-title":"Two-Year follow-up from the T1GER Study:Continued off-therapy metabolic improvements in children and young adults with new-onset T1D treated with golimumab and characterization of responders","volume":"46","author":"Rigby","year":"2023","journal-title":"Diabetes Care"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1038\/s41467-022-35544-3","article-title":"A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes","volume":"13","author":"Martin","year":"2022","journal-title":"Nat Commun"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"e061776","DOI":"10.1136\/bmjopen-2022-061776","article-title":"Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype:The DIAGNODE-3 study protocol","volume":"12","author":"Ludvigsson","year":"2022","journal-title":"BMJ Open"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13063-022-06356-z","article-title":"Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial","volume":"23","author":"Waibel","year":"2022","journal-title":"Trials"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes:A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"e3440","DOI":"10.1002\/dmrr.3440","article-title":"Combined etanercept, GAD-alum and vitamin D treatment:An open pilot trial to preserve beta cell function in recent onset type 1 diabetes","volume":"37","author":"Ludvigsson","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00125-020-05317-y","article-title":"A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"Keymeulen","year":"2021","journal-title":"Diabetologia"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"dgaa149","DOI":"10.1210\/clinem\/dgaa149","article-title":"Randomized 52-week Phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes","volume":"105","author":"Pozzilli","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","article-title":"Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes:2 year results of a randomised trial","volume":"59","author":"Gitelman","year":"2016","journal-title":"Diabetologia"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI78492","article-title":"Anti-thymocyte globulin\/G-CSF treatment preserves \u03b2 cell function in patients with established type 1 diabetes","volume":"125","author":"Haller","year":"2015","journal-title":"J Clin Invest"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","article-title":"Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes:12-month results of a randomised, placebo-controlled, phase 2 trial","volume":"1","author":"Gitelman","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41467-022-28826-3","article-title":"Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_122_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:14:21Z","timestamp":1787760861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_122_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_122_23","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2023-03-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}